Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. Photo via uh.edu

A Houston philanthropist made a $2 million gift to the University of Houston to advance health care business innovation

Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. The Elaine W. Finger Endowed Chair in Health Care Business Innovation is a joint appointment in the C.T. Bauer College of Business and the Tilman J. Fertitta Family College of Medicine. The project will aim to catalyze innovative advancements to help the university into a leading hub for innovative solutions.

The endowment was made through the Bauer Foundation, and will be matched dollar-for-dollar via UH’s Aspire Fund. The Aspire Fund is a grant program created by the gift of an anonymous donor that matches all eligible gifts up to $50 million — for a total of $100 million — and is aimed to assist in education, health care innovation research, and industry outreach.

“An investment in health care business innovation is far more than a gift, it is a visionary commitment to the future of healthcare in Houston and beyond,” Diane Z. Chase, UH senior vice president for academic affairs and provost, says in a news release. “The establishment of this Chair is a testament to our shared dedication to developing solutions that will shape the health care landscape for generations to come.”

Bauer College launched the Healthcare Business Institute, or HBI, this summer to address research and innovative solutions for quality, cost and access concerns. HBI also works to connect students, faculty and researchers from Bauer, the Fertitta Family College of Medicine and the highly ranked health law program at the UH Law Center, and other UH programs.

UH will search for a new chair that according to the university, “will be considered a thought leader in health care innovation" and who is of high national prominence and able to elevate the stature of the University of Houston by bringing a record of achievements recognized by membership in the National Academy of Science, National Academy of Medicine or another national academy related to the field of study.

Ravi Aron, research director and professor of health care strategy, currently leads HBI.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

West Coast innovation organization unveils new location in Houston suburb to boost Texas tech ecosystem

plugging in

Leading innovation platform Plug and Play announced the opening of its new flagship Houston-area location in Sugar Land, which is its fourth location in Texas.

Plug and Play has accelerated over 2,700 startups globally last year with corporate partners that include Dell Technologies, Daikin, Microsoft, LG Chem, Shell, and Mercedes. The company’s portfolio includes PayPal, Dropbox, LendingClub, and Course Hero, with 8 percent of the portfolio valued at over $100 million.

The deal, which facilitated by the Sugar Land Office of Economic Development and Tourism, will bring a new office for the organization to Sugar Land Town Square with leasing and hiring between December and January. The official launch is slated for the first quarter of 2025, and will feature 15 startups announced on Selection Day.

"By expanding to Sugar Land, we’re creating a space where startups can access resources, build partnerships, and scale rapidly,” VP Growth Strategy at Plug and Play Sherif Saadawi says in a news release. “This location will help fuel Texas' innovation ecosystem, providing entrepreneurs with the tools and networks they need to drive real-world impact and contribute to the state’s technological and economic growth."

Plug and Play plans to hire four full-time equivalent employees and accelerate two startup batches per year. The focus will be on “smart cities,” which include energy, health, transportation, and mobility sectors. One Sugar Land City representative will serve as a board member.

“We are excited to welcome Plug and Play to Sugar Land,” Mayor of Sugar Land Joe Zimmerma adds. “This investment will help us connect with corporate contacts and experts in startups and businesses that would take us many years to reach on our own. It allows us to create a presence, attract investments and jobs to the city, and hopefully become a base of operations for some of these high-growth companies.”

The organization originally entered the Houston market in 2019 and now has locations in Bryan/College Station, Frisco, and Cedar Park in Texas.